Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

European Journal of Cancer

Volumn 48, Issue 13, 2012, Pages 2012-2019

  Brandberg, Y ^a   Aamdal, S ^b   Bastholt, L ^c   Hernberg, M ^d   Stierner, U ^e   Von Der Maase, H ^f,g   Hansson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f Mental Health Services CPH   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Health related quality of life; High risk; Interferon; Malignant melanoma; Randomised

Indexed keywords

ALPHA2B INTERFERON;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHILL; CONTROLLED STUDY; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEADACHE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUSCLE STIFFNESS; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; QUALITY OF LIFE; RECOMBINANT PROTEINS; RISK; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84865109234     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.019     Document Type: Article

References (25)

1. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstoff Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17 (Pubitemid 26019991)
2. J. Hansson, S. Aamdal, and L. Bastholt Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomized phase 3 trial Lancet Oncol 12 2011 144 152
3. E.M. McDonald, A.H. Mann, and H.C. Thomas Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers Lancet 2 1987 1175 1178
4. A. Ravaud, C. Bedane, L. Geoffrois, T. Lesimple, and M. Delaunay Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice Br J Cancer 80 1999 1767 1769 (Pubitemid 29389630)
5. P.C. Trask, P. Esper, M. Riba, and B. Redman Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions J Clin Oncol 18 2000 2316 2326 (Pubitemid 30350225)
6. P.C. Trask, A.G. Paterson, P. Esper, J. Pau, and B. Redman Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon Psychooncology 13 2004 526 536 (Pubitemid 39149241)
7. S. Dixon, S.J. Walters, L. Turner, and B.W. Hancock Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from a randomized trial Br J Cancer 94 2006 492 498 (Pubitemid 43289752)
8. D. Rataj, E. Krajewska-Kulak, and B. Jankowiak Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients Cancer Nurs 28 2005 172 178 (Pubitemid 40734535)
9. A. Bottomley, C. Coens, and S. Suciu Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 27 2009 2916 2923
10. S. Ziefle, F. Egberts, and S. Heinze Health-related quality of life before and during adjuvant interferon-α treatment for patients with malignant melanoma (DeCOG-trial) J Immunother 34 2011 403 408
11. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Nat Cancer Inst 85 1993 365 376 (Pubitemid 23073154)
12. P.M. Fayers, N.K. Aronson, and K. Bjordal The EORTC QLQ-C30 scoring manual 3rd ed. 2001 European Organization for Research and Treatment of Cancer Brussels
13. B. Bergman, M. Sullivan, and S. Sörenson Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile Acta Oncol 31 1992 19 28
14. V. Sigurdardottir, Y. Brandberg, and M. Sullivan Criterion-based validation of the EORTC QLQ-C36 in advanced melanoma: the CIPS questionnaire and proxy raters Qual Life Res 5 1996 375 386 (Pubitemid 26228470)
15. H. Michelson, C. Bolund, B. Nilsson, and Y. Brandberg Health-related quality of life measured by the EORTC QLQ-C30 - reference values from a large sample of Swedish population Acta Oncol 39 2000 477 484
16. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 1998 139 144 (Pubitemid 28041591)
17. B.W. Hancock, K. Wheatley, and S. Harris Adjuvant interferon in high-risk melanoma: the AIM-HIGH- study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma J Clin Oncol 22 2004 53 61 (Pubitemid 41095114)
18. A.G. Paterson, P.C. Trask, L.I. Wagner, P. Esper, and B.I. Redman Validation of the FACT-BRM with interferon-alpha treated melanoma patients Qual Life Res 14 2005 133 139 (Pubitemid 40249087)
19. S. Donnelly Patient management strategies for interferon alpha-2b as adjuvant therapy of high-risk melanoma Oncol Nurs Forum 25 1998 921 927
20. D.L. Musselman, D.H. Lawson, and J.F. Gumnick Paroxetine for the prevention of depression induced by high-dose interferon alfa N Engl J Med 344 2001 961 966 (Pubitemid 32240314)
21. L. Capuron, A. Ravaud, and R. Dantzer Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alpha-2b therapy J Clin Oncol 18 2000 2143 2151 (Pubitemid 30324368)
22. P. Mohr, A. Hauschild, U. Trefzer, and M. Weichenthal Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma J Clin Oncol 27 2009 e7
23. C.M. Bender, J.M. Yasko, and J.M. Kirkwood Cognitive function and quality of life in interferon therapy for melanoma Clin Nurs Res 9 2000 352 363
24. A. Hurria, G. Somlo, and T. Ahles Renaming "chemobrain" Cancer Invest 25 2007 373 377
25. S. Taillibert, D. Voillery, and C. Bernard-Marty Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 19 2007 623 627 (Pubitemid 47508872)